Four ADRIC mutations that occur close to Ser-230 of the Saccharomyces cerevisiae transcriptional activator ADR1 and which greatly enhance the ability of ADR1 to activate ADH2 expression under glucose-repressed conditions have been shown to reduce or eliminate cyclic AMP-dependent protein kinase (cAPK) phosphorylation of Ser-230 in vitro. In addition, unregulated cAPK expression in vivo blocks ADH2 derepression in an ADRI-dependent fashion in which ADRIC mutations display decreased sensitivity to unregulated cAPK activity. Taken together, these data have suggested that ADRIC mutations enhance ADR1 activity by blocking cAPK phosphorylation and inactivation of Ser-230. We have isolated and characterized an additional 17 ADRIC mutations, defining 10 different amino acid changes, that were located in the region defined by amino acids 227 through 239 of ADR1. Three observations, however, indicate that the ADRIC phenotype is not simply equivalent to a lack of cAPK phosphorylation. First, only some of these newly isolated ADRIC mutations affected the ability of yeast cAPK to phosphorylate corresponding synthetic peptides modeled on the 222 to 234 region of ADR1 in vitro. Second, we observed that strains lacking cAPK activity did not display enhanced ADH2 expression under glucose growth conditions. Third, when Ser-230 was mutated to a nonphosphorylatable residue, lack of cAPK activity led to a substantial increase in ADH2 expression under glucose-repressed conditions. Thus, while cAPK controls ADH2 expression and ADR1 is required for this control, cAPK acts by a mechanism that is independent of effects on ADRI Ser-230. It was also observed that deletion of the ADRiC region resulted in an ADRIC phenotype. The ADR1C region is, therefore, involved in maintaining ADR1 in an inactive form. ADRIC mutations may block the binding of a repressor to ADR1 or alter the structure of ADR1 so that transcriptional activation regions become unmasked.
The regulation of the glucose-repressible alcohol dehydrogenase (ADH II, encoded by the ADH2 gene) from Saccharomyces cerevisiae is mediated by several pathways. The SNF1 protein kinase and the REGI gene constitute one pathway (10, 35) , but their site of action at ADH2 has not been identified. The transcriptional activator ADR1 acts independently of SNFI (10) and binds to the upstream activation sequence, UAS1, located between bp -271 and -291 of the ADH2 promoter (39) . Part of the glucose regulation of ADH2 is mediated by control of ADR1 translation (37a) . A third regulatory network whose factors have not been identified may act through UAS2, which is just upstream of UAS1 (39) .
The importance of ADR1 in the glucose control of ADH2 is evidenced by a class ofADRI mutations (ADRJC) causing enhancedADH2 transcription under repressed conditions (8, 11) . These mutations do not affect ADR1 RNA (12) or protein levels (37a) and must activate ADR1 by a posttranslational mechanism. Four ADRlC mutations have been identified and found to occur between amino acids 228 and 231 of ADR1 in a putative cyclic AMP-dependent protein kinase (cAPK) phosphorylation consensus sequence (RRASF, where Ser-230 is the phosphoacceptor) (6, 12) . ADR1 has been found to be a substrate for cAPK in vitro; cAPK phosphorylates both Ser-230 and some other site to the N-terminal side of Ser-230 (6) . The ADR1C mutations were shown to decrease or eliminate cAPK phosphorylation of ADR1 at Ser-230 in vitro. These data suggest that in S. cerevisiae the ADRlC alterations enhance ADR1 activity by interfering with the cAPK phosphorylation of Ser-230.
Subsequent genetic analysis indicated that unregulated cAPK activity, the result of disrupting the BCY1 cAPK regulatory gene, reduces ADH2 expression (6) . The effects of the bcyl disruption were relieved, albeit incompletely, by ADRJC mutations (6) . These results provided support for the model that cAPK inactivated ADR1 function by phosphorylating Ser-230, although Ser-230 appeared not to be the only site of cAPK inactivation. More recently it has been demonstrated that all of the effects of cAPK onADH2 expression are mediated by ADR1 (10) . Two other protein kinases, SNF1 and SCH9, were observed to affect ADH2 expression independently of both ADR1 and cAPK (10) .
In this study, we have characterized 17 additional ADRJC alleles with the expectation of furthering our understanding of how these mutations activate ADR1. Using synthetic peptides, we observed that not allADRlC mutations affected the cAPK phosphorylation of Ser-230 in vitro. More importantly, lack of cAPK activity did not elicit an ADRlC phenotype in vivo. These data argue for a model in which ADRJC mutations alter the structure and function of ADR1 independent of cAPK phosphorylation of Ser-230. In addition, when Ser-230 could not be phosphorylated, a lack of cAPK was observed to result in enhanced ADR1 function. Accordingly, cAPK must act through another site on ADR1 or through another protein that mediates ADR1 activity. b Amino acid changes are given in the format A229P, where A represents the residue in the ADRI gene, the number refers to the residue, and P refers to the residue encoded by the ADRJC allele.
MATERIALS AND METHODS
Yeast strains. Yeast strains are listed in Table 1 . Strains containing the ADRI alleles 9C through 25C were isogenic to 315-1D (32) .
Identifying ADRIC mutations. Strains containing dominant mutations that allowed ADH2 expression under glucose growth conditions were obtained by V. Williamson in the course of a previous study (32) . Each mutant was an independent spontaneous isolate and was shown not to result from Ty insertions at either the ADH2 orADH4 locus (32) . Tetrad analysis was used to determine whether the dominant mutations mapped to the ADRI locus. ADRIC alleles were rescued from S. cerevisiae and localized to the region between bp +440 and + 1076 as described previously (6, 12) . For each different ADRJC allele, the region between bp +440 and + 1076 was sequenced to identify the ADRlC lesion.
cAPK phosphorylation of synthetic ADR1 peptides. Peptides were synthesized and isolated as described previously (13) . The yeast TPK1 (37) enzyme was provided by M. Zoller, and the porcine heart cAPK was provided by S. Taylor. Conditions for determining the Km of phosphorylation of each peptide were as described previously (13) . The unique site of phosphorylation for each peptide, except ADR1-222-234 (F231S), was determined to be Ser-230 by chymotryptic analysis as described previously (13) . Peptide ADR1-222-234 (F231S) was found to be stoichiometrically phosphorylated on serine, but the precise site of phosphorylation was not determined.
Growth conditions and ADH assays. Conditions for growth of cultures on YEP medium (2% Bacto Peptone, 1% yeast extract, 20 mg of adenine and uracil per liter) have been described previously (15) . ADH II enzyme activities were assayed as previously described (10, 15) . Yeast transformations were conducted by the LiAcetate procedure (22) .
Gene disruptions and constructions. The BCYJ gene disrupted with the LEU2 gene was used as previously described (36) . The tpk2wll, the tpklwlO, and the tpk3wll through -14 alleles were specifically selected as suppressors of bcylinduced phenotypes (inability to grow at 30°C after a shift to 55°C for 1 h, dark colony color, and reduced growth on nonfermentative carbon sources) as previously described (5, 31) . Genetic analysis was conducted as previously described (5) to verify that a tpkw allele was responsible for suppressing the unregulated cAPK activity caused by the bcyl allele. cAPK enzyme activity was determined as described previously (36) .
ADRJ-220/262 was constructed as follows. The XmnISacI fragment of ADRI (bp 786 to 1713) was ligated into pUC18 at the SmaI (blunt-ended) and SacI sites to generate plasmid LBp45. The HindIII-ScaI fragment of YRp7-ADR1-23A (12), extending from 1.5 kbp upstream of ADRI to bp +661, was subsequently ligated into LBp45 restricted with HindIII and Sall (filled in with a Klenow fragment). The resultant plasmid, LBp8, contained the 5' region of ADR1 and the region encoding ADR1 amino acids 1 to 220 placed in frame to residues 262 to 571. Between residues 220 and 262 were seven additional amino acid residues derived from the pUC18 polylinker (FDSRGSP). LBp8, after addition of the TRPI gene, was targeted for integration at the adri-l locus in strain 500-16 following cleavage with NruI at bp 1517. Identification of integrants by genetic and Southern analysis has been described previously (2) . Integration of the plasmid LBp8 (TRPI) at the adrl-l locus regenerates a complete ADRI-2201262 allele as well as a truncated adrl-l allele. adrl-l does not express a functional ADR1 protein, since it contains a nonsense mutation in its 11th codon (3). 
RESULTS
Identification of 17 newADRic mutations. Twenty independently isolated strains containing dominant mutations which allowed glucose-insensitive ADH2 expression and which were not the result of Ty transposition at either the ADH2 or ADH4 locus (32) were analyzed. Tetrad analysis indicated that 18 of these contained mutations at the ADR1 locus (ADRIC) and 2 carried mutations atADH2 (data not shown). Of the ADRlC alleles, 17 were rescued from S. cerevisiae, and the ADRlC lesions were localized and sequenced. All 17 mutations were found to result from single base pair changes (Table 2) . Ten different amino acid changes that defined eight newADRlc mutations (R228K and S230L had been obtained previously) (6, 12) that substitute amino acids in the region of residues 227 to 239 of ADR1 ( Fig. 1) were identified. These new mutations occurred in the same region of ADR1 as did the previous fourADRlC mutations that surround Ser-230 (6, 12) . The occurrence of all 21 known ADRIC mutations in the region containing Ser-230 suggests that this is the only domain of ADR1 which can be mutated to allow ADR1 to bypass the effects of glucose repression.
The effect on ADH2 expression of each of the different ADRJC mutations is given in LT RR AS FS A QS (2) FIG. 1. Amino acid changes corresponding toADRIC mutations. The amino acid changes for the ADR1C mutations are indicated below the ADR1 sequence that extends from amino acids 227 to 240. The number below the amino acid change indicates the number of independently isolated alleles giving rise to that change. The numbers above the ADR1 sequence refer to the ADR1 protein sequence.
of the newly identified ADR1C mutations appeared unlikely, however, to similarly affect cAPK phosphorylation. It is known that some mammalian cAPK substrates, e.g., the CREB protein (19) and fructose-1,6-bis-phosphatase (17) , are phosphorylated effectively at the sequence RRPS, a sequence identical to that found in ADR1C-A229P (Table 3) . Also, it has been shown that a proline at the -1 position (relative to the phosphoacceptor site designated 0) has little or no effect on phosphorylation of synthetic peptide substrates (7, 13, 17, 20) . In addition, the yeast cAPK regulatory subunit BCY1, a known in vivo substrate for yeast cAPK, contains a glycine residue in its +3 position, resulting in a sequence (RRASVSG) (36) which is very similar to that of ADR1-11C-A233G (RRASFSG) ( Table 4) . We therefore examined whether the ADRlC mutations were likely to affect cAPK phosphorylation by using synthetic peptides modeled on the sequence containing Ser-230 of ADR1.
Synthetic peptides have generally been found to be excellent substrates for mammalian cAPK and to be phosphorylated with kinetics similar to those of the natural protein substrates (24) . Moreover, synthetic peptides modeled on the ADRI sequence at Ser-230 have previously been shown to be excellent substrates for yeast cAPK (TPK1 isozyme) (13) . ADR1-222-234, which is phosphorylated with a Km of 6.8 ,uM by the yeast TPK1 enzyme (Table 4) , was chosen as our parent substrate (13) . Eight different ADR1 peptide analogs were synthesized, each containing an amino acid change corresponding to an ADRJC mutation, and the ability of each peptide to be phosphorylated by yeast cAPK was analyzed. Some ADRJC mutations causing alterations in previously known important recognition determinants of cAPK (e.g., R227L, R228K, F231S, and S232R) (4, 24) had very dramatic effects on cAPK phosphorylation of Ser-230. These alterations increased the Km for phosphorylation by 20-to 400-fold (Table 4) . These results are in agreement with our previous data demonstrating that R228K and F231S reduce the ability of cAPK to phosphorylate Ser-230 in vitro (6) . In contrast, other ADRIC mutations had very little or no effect on cAPK phosphorylation (e.g., A229P, S2321, A233G, and A233T) ( Table 4 ). In fact, we observed no correlation between cAPK recognition of the ADRlC peptide analogs and the ability of the ADR1 or ADRlC protein to activate ADH2 under glucose growth conditions (Table 3) . These results do not appear to be due to some special recognition feature of the yeast TPK1 isozyme, since similar effects on Ser-230 phosphorylation were also obtained with the distantly related porcine cAPK (Table 4 ). In addition, the recently determined crystal structure of mouse cAPK clearly indicates that the A229P change would not be expected to affect cAPK phosphorylation (26) . These data do not support the model that the only effect of the ADRlC mutations on ADR1 function is to alter cAPK phosphorylation of Ser-230. Lack of cAPK activity does not confer an ADR1C phenotype. Because the results described above were conducted in vitro, we acknowledge the possibility that the ADRlC alterations could result in gross changes in the structure of the full-length ADR1 protein that would affect cAPK phosphorylation of Ser-230 in vivo. To address this question, we analyzed in vivo the effect of a lack of cAPK activity on ADH2 expression. If the ADRlC phenotype were due solely to reducing cAPK phosphorylation of Ser-230, then strains containing no measurable cAPK activity would be expected to evince an ADRIC phenotype. We investigated this possibility by measuring the level of ADH2 expression in strains containing deletions in two of the three TPK genes and a mutation in the third TPK gene (tpkw allele). Such strains lack measurable cAPK activity (reference 5 and Materials and Methods above) and are known to be refractory to the effects of disrupting the BCYI gene, a disruption that would otherwise cause unregulated cAPK activity (5). Our analysis of strains lacking cAPK activity indicated that the levels of ADH II expression under glucose growth conditions were unaltered from those found in wild-type strains (Table 5) . These results were observed regardless of the combination of deleted and mutated TPK alleles (Table 5 and data not shown). Under ethanol growth conditions, however, lack of cAPK activity relieved the reduction in ADH2 expression caused by unregulated cAPK activity (e.g., compare strains isogenic to 410-ic [ Table 5 ]), indicating that strains containing disruptions in two TPK genes and a mutation in the third behaved as though they lacked cAPK activity.
While it can be argued that under glucose growth conditions trace levels of cAPK activity that fall below our detection capabilities may persist and be sufficient to maintain glucose repression of ADR1, several observations suggest that this is not the case. First, similar strains lacking detectable cAPK activity in an ADR1-7C background (con- a ADH II enzyme activities were determined as described in Table 3 , footnote a. Strains derived from the same background strain are isogenic, except for the disrupted allele indicated in the table. The tpklwl allele has been previously described (5 Table 3, footnote a. The tpklwlO and tpk3wll, tpk3wl2, tpk3wl3, and tpk3wl4 alleles were identified as described in Materials and Methods. Strains derived from the same background strain are isogenic, except for the disrupted and mutated tpkw alleles as indicated. 409-7c strains containing the ADRI-7' and ADRI-'S alleles were derived by integration of plasmids YRp7-ADR1-7c-23A and YRp7-ADR1-5c-23A, respectively, into strain 409-7c (6). ND, not determined. b Plasmid YEp24-BCY1 that contains the full-length BCYJ gene (36) was transformed into the parental strain 409-7c-1-wll (tpk3wll bcyl). In order to select for YEp24-BCY1 transformants, isolates of strain 409-7c-1-wll that contained a defect in the URA3 gene were first identified following exposure to 5-fluoro-orotic acid (38) .
strains carrying the ADR1-7' allele. We presumed that the ADRI-7c (S230L) mutation causes a conformational change in ADR1 that may mimic ADR1 structure, either partially or completely, under ethanol growth conditions. In such a case, the effect of a lack of cAPK activity on ADR1 activity and ADH2 expression might become discernible. Strain 409-7c carrying theADRJ-7' allele and a single functional TPK gene (TPK3) was analyzed (Table 6 ). ADH2 expression decreased about twofold under glucose growth conditions when the BCYI gene was disrupted (6) ( Table 6 ). When the remaining TPK gene was mutated (allele tpk3wll) to generate a yeast strain containing no measurable cAPK activity (data not shown), ADH2 expression increased to a level that was 15-fold higher than that found in the parental strain containing a functional TPK3 allele. ADH2 expression also increased under ethanol growth conditions (Table 6) . A similar increase (eightfold) in ADH2 expression under glucose growth conditions was obtained with another strain carrying the ADRI-7' allele and lacking cAPK activity as demonstrated with a second set of isogenic strains (639-3b strains [ Table 6 ]), confirming that these results are not strain dependent. These results are not specific to these tpk3w alleles, since eight additional independently isolated tpk3w alleles in strain 639-3b resulted in ADH II enzyme levels under glucose growth conditions that ranged from 730 to 950 mU/mg. We also tested whether the ADR1-5C allele (R228K) behaved in a similar manner. A strain lacking cAPK activity in an ADR1-SC background expressed threefold more ADH II activity under glucose growth conditions and twofold more under ethanol conditions than an isogenic strain containing cAPK activity (Table 6 ). These observations are also not limited to tpk3w alleles, since similar results were obtained in an ADR1-7C-containing strain that carried tpk2 and tpk3 disruptions and a tpklw allele (Table 6 ). In addition, we tested whether the bcyl disruption was influencing the high activities under glucose growth conditions by transforming strain 409-7c, which lacked cAPK activity, with a plasmid containing the BCYI gene (36) . Elevated levels of ADH2 expression were still observed in a strain with the ADRI-7' allele that lacked cAPK activity but contained a functional BCYI gene (Table 6 ).
In order to examine whether the effects described above were the result of the ADRJC alleles or were caused by a general increase in ADH2 transcription, the effect of a lack of cAPK activity on a strain carrying the crel allele was also analyzed. crel mutations under glucose growth conditions enhance ADH2 transcription in an ADR1-independent manner to a level similar to that observed with anADRI-7' allele (14) . Deletion of the BCYJ gene in a crel background resulted in a 25% reduction in ADH2 expression under glucose growth conditions compared with that of the parental strain (Table 6 ). When the TPK3 allele was also mutated, a return to a level of ADH2 expression commensurate with that observed in the strain containing cAPK activity was obtained (Table 6 ). These results are essentially the same as that obtained with a strain carrying the wild-type CRE1 and ADR1 genes ( Table 5 ). The enhanced ADH2 expression that is observed with lack of cAPK in anADRJ-7 background is, therefore, not the result of a general elevated level ofADH2 transcription. Instead, it is dependent on the ADRlC allele. These results suggest that cAPK inactivates ADH2 transcription through a site separate from Ser-230 of ADR1 and that the structure of the region around Ser-230 (as in an ADRI-7' allele) potentiates this effect of cAPK on ADH2 expression.
Deletion of the ADR1C region confers an ADRlC phenotype. The results described above suggest a lack of correlation between ADRJC mutations and cAPK phosphorylation of Ser-230 but do not reveal the importance of the sequence of the ADRlC region in ADR1 function. An internal in-frame deletion between amino acids 220 and 262 of ADR1, the entire ADRlC region, was constructed and integrated as a single copy into the genome to address this question. The resulting ADR1-220/262 allele was found to result in an ADH2 phenotype that was very similar to that obtained with the ADRiC mutations (Table 3) . Under glucose growth conditions, ADH2 expression in the strain carrying the deletion was observed to be 30-fold higher than that found in a wild-type strain. We also observed that this effect of ADRI-220/262 on ADH2 expression was not a result of a corresponding increase in the level of ADR1-220/262 protein in the cell relative to the level of ADR1 protein as quantitated by immunoprecipitation of ADR1-220/262 (data not shown) (9) . The observation that the deletion of the residues between 220 to 262 resulted in elevated ADH2 expression suggests, therefore, that the ADRlC region plays a negative role in ADR1 function. These results support the model that the ADRJC mutations enhance ADR1 activity by altering the structure of the region and therefore its contact with another protein or another region of ADRI.
DISCUSSION
Our previous studies indicated that ADRI' mutations reduce or eliminate cAPK phosphorylation of Ser-230 in vitro (6) . Unregulated cAPK was subsequently shown to inhibit ADH2 expression (6) in an ADR1-dependent manner (10) . ADRJC mutations displayed reduced sensitivity to unregulated cAPK activity (6) . These results suggested that cAPK inactivates ADH2 expression by inhibiting ADRI function through phosphorylation of Ser-230.
The data we present here, however, do not support the model that the ADRIC mutations enhance ADRI function by solely affecting cAPK phosphorylation of Ser-230. We observed that several newly characterized ADRIC mutations did not affect the ability of cAPK to phosphorylate Ser-230 on synthetic peptides modeled on the ADRI' region. Most importantly, we found that strains lacking cAPK activity did not evince an ADRI' phenotype. The ADRI' mutations, therefore, must be activating ADR1 by a mechanism that is independent of interference with cAPK phosphorylation of Ser-230. Moreover, it was observed that when ADRI residue 230 could not be phosphorylated, the lack of cAPK caused an increase in ADR1 function. This result supports the observation that the cAPK regulation of ADH2 does not occur directly through phosphorylation of Ser-230. Thus, the previous model suggesting that Ser-230 of ADR1 was the site of this inactivation is probably incorrect.
Our previous papers (6, 10) and the present data (Tables 5  and 6 ) clearly indicate that cAPK inhibits ADH2 expression. That this inhibition is physiologically relevant and is not an artifact of unregulated cAPK activity is evidenced by the observation that lack of cAPK activity augmented ADH2 expression in an ADRI-7 background (Table 6) . We have also established that ADRI function is required for the effect of unregulated cAPK activity on derepressed ADH2 expression (10 (Table 3 ). Because we demonstrated that deletion of the ADRI' region (removal of amino acids 220 to 262) conferred an ADR1' phenotype, the region where these mutations are located represents an inhibitory domain of ADRI. This domain may bind a repressor (see Fig. 2B ) that maintains ADR1 in an inactive state through inhibition of its ability to activate transcription. ADRiC alterations would prevent the repressor from binding to ADRI. Alternatively, the ADRiC domain may block the ability of another segment of ADR1 to activate transcription through an intrasteric interaction ( Fig. 2A) Many other eucaryotic transcriptional activators contain regions which serve to inhibit their ability to turn on transcription. These include the yeast activators GAL4 (23, 28) and PUT3 (29) , as well as the mammalian factors CREB (18), C/EBP (34) , and c-Myb (27) . Restricting an activator's ability to stimulate transcription by the binding of a mask appears, therefore, to be a common mechanism. The masks may be other proteins that bind and repress function, as in the GAL80 inhibition of GAILA (23, 28) , or they may be internal regions that block the activation function through an intrasteric interaction. This phenomenon resembles that of pseudosubstrate regulation, which was first clearly outlined for protein kinases (for a review, see reference 25) . The pseudosubstrate mimics the substrate and binds at the active site, preventing the protein kinase from phosphorylating its normal target substrates. The pseudosubstrate may be located either on a different protein, as is the case with cAPK (33), or on the same protein, as found for myosin light chain protein kinase and protein kinase C (21, 33) . For the transcriptional activators, it is not clear whether the inhibitory domains resemble the factors to which the activation domains bind or whether the inhibitory regions indirectly block the activation regions.
It should also be noted that lack of cAPK activity in an ADR1-7 background caused an 8-to 15-fold increase in ADH2 expression under glucose-repressed conditions but resulted in only a twofold elevation under ethanol growth conditions. This discrepancy is most likely due to the fact that under glucose conditions ADH2 expression is strictly ADR1-dependent, whereas under derepressed conditions other factors are clearly limiting (9) . Enhancing the ability of ADR1 to activate results in large effects on ADH2 expression under repressed conditions but produces much smaller effects under derepressed conditions (2, 9) .
